Fundraisings and IPOs

* On April 24, 2013, Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), has announced that it has raised €18.2 million (USD 23,7 million) in additional capital. Wellington Partners, based in Munich, Germany, led the round which included all current institutional investors i.e. IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund*, IRDI and Amundi Private Equity Funds. Dr. Rainer Strohmenger, General Partner at Wellington Partners, joins the Supervisory Board of Genticel.

The new funds will be used to advance Genticel’s key product candidates, i.e., two therapeutic HPV vaccines. The lead vaccine, ProCervix, has successfully finished phase I clinical study. The phase I trial (n=47) revealed no dose limiting toxicity and no patient drop-out. In addition, ProCervix induced a dose-dependent immune response as well as viral clearance in a substantially larger percentage of patients as compared to placebo. ProCervix will enter into phase II development in order to demonstrate proof of efficacy. This bivalent product, built on Genticel’s proprietary CyaA antigen delivery technology, carries antigens originating from both HPV16 and HPV18. Genticel’s other pipeline product is a CyaA-based multivalent HPV vaccine with additional virus subtype coverage.